Spark Therapeutics Follow-On Offering

Davis Polk advised the representative of the underwriters in connection with the $402.5 million public offering of 5,296,053 shares of common stock of Spark Therapeutics, Inc. The common stock is listed on the NASDAQ Global Select Market under the symbol “ONCE.”

Spark Therapeutics, a fully integrated company, strives to challenge the inevitability of genetic disease by discovering, developing and delivering gene therapies that address inherited retinal diseases, neurodegenerative diseases as well as diseases that can be addressed by targeting the liver, such as hemophilia.

The Davis Polk corporate team included partner Richard D. Truesdell Jr. and associates Cameron C. Lewis and Chris Van Buren. Counsel David R. Bauer and associate Bonnie Chen provided intellectual property and technology advice. Counsel Marcie A. Goldstein provided FINRA advice. Partner Rachel D. Kleinberg and associate Dao Fu provided tax advice. Members of the Davis Polk team are based in the New York and Northern California offices.